tbuckley/cabot-search huggingface dataset:
Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer
Authors: Liye Zhou, Tenny Mudianto, Xiaojing Ma, Rachel Riley, Ravindra Uppaluri
Journal: Clinical Cancer Research (2019)

Anti-programmed death-1 (PD-1) receptor-based therapeutics improve survival in patients with recurrent head and neck squamous cell carcinoma (HNSCC), but many do not benefit due to a low response rate. Herein, we identified EZH2 as a therapeutic target that enhanced tumor cell antigen presentation and subsequently sensitized resistant tumors to anti-PD-1 therapy.EZH2 regulation of antigen presentation was defined using EZH2 inhibitors (GSK126 and EPZ6438) in human and mouse HNSCC cell lines. Mechanistic dissection of EZH2 in regulation of antigen presentation was investigated using flow cytometry, qRT-PCR, ELISA, and chromatin-immunoprecipitation assays. EZH2-deficient cell lines were generated using CRISPR-CAS9. GSK126 and anti-PD-1-blocking antibody were used in testing combinatorial therapy in vivo.EZH2 expression was negatively correlated with antigen-processing machinery pathway components in HNSCC data sets in The Cancer Genome Atlas. EZH2 inhibition resulted in significant upregulation of MHC class I expression in human and mouse human papillomavirus-negative HNSCC lines in vitro and in mouse models in vivo. Enhanced antigen presentation on the tumor cells by EZH2 inhibitors or CRISPR-mediated EZH2 deficiency increased antigen-specific CD8+ T-cell proliferation, IFNγ production, and tumor cell cytotoxicity. Mechanistically, EZH2 inhibition reduced the histone H3K27me3 modification on the β-2-microglobulin promoter. Finally, in an anti-PD-1-resistant model of HNSCC, tumor growth was suppressed with combination therapy.Our results demonstrated that targeting EZH2 enhanced antigen presentation and was able to circumvent anti-PD-1 resistance. Thus, combining EZH2 targeting with anti-PD-1 may increase therapeutic susceptibility in HNSCC.
TCT-507 Network Latency and Long-Distance Robotic Telestenting: Exploring the Potential Impact of Network Delays on Telestenting Performance
Authors: Paulina Phomvongsa, Stacie VanOosterhout, Jared Bush, Adam Rash, Jose Mariano Tan, Jessica Parker, Andrew Kalafut, Li Yao, Nicholas Kottenstette, Per Bergman, Brent Nowak, Ryan Madder
Journal: Journal of the American College of Cardiology (2019)
Cardiovascular medicine and research in sub-Saharan Africa: challenges and opportunities
Authors: Liesl Zühlke, Karen Sliwa, Pamela Naidoo, Hopewell Ntsinjana, Mpiko Ntsekhe, Farrel Hellig, Francis Smit, David Jankelow, Saad Subahi, Rob Dyer, Erika Dau, Ntobeko A. B. Ntusi
Journal: Nature Reviews Cardiology (2019)
TCT-610 Impact of Baseline Renal Function on the Long-Term Clinical Outcomes After PCI: Insights From a Prespecified Subgroup Analysis of the Randomized GLOBAL LEADERS Trial
Authors: Mariusz Tomaniak, Ply Chichareon, Dominika Klimczak, Norihiro Kogame, Rodrigo Modolo, Kuniaki Takahashi, Chun-Chin Chang, Hidenori Komiyama, Tessa Rademaker-Havinga, Nick Curzen, Michael Haude, Christian Hamm, Philippe Gabriel Steg, Peter Juni, Yoshinobu Onuma, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Richard Anderson, Patrick Serruys
Journal: Journal of the American College of Cardiology (2019)
Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits
Authors: Sophie E. Legge, Hannah J. Jones, Kimberley M. Kendall, Antonio F. Pardiñas, Georgina Menzies, Matthew Bracher-Smith, Valentina Escott-Price, Elliott Rees, Katrina A. S. Davis, Matthew Hotopf, Jeanne E. Savage, Danielle Posthuma, Peter Holmans, George Kirov, Michael J. Owen, Michael C. O’Donovan, Stanley Zammit, James T. R. Walters
Journal: JAMA Psychiatry (2019)

Psychotic experiences, such as hallucinations and delusions, are reported by approximately 5% to 10% of the general population, although only a small proportion develop psychotic disorders such as schizophrenia. Studying the genetic causes of psychotic experiences in the general population, and its association with the genetic causes of other disorders, may increase the understanding of their pathologic significance.
Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients
Authors: Meral Beksac, Yildiz Aydin, Hakan Goker, Mehmet Turgut, Sevgi Kalayoglu Besisik, Seckin Cagirgan, Tulin F Tuglular, Filiz Vural, Munci Yagci
Journal: Blood (2017)
TCT-760 30-Day Echocardiographic Assessment of Self-Expanding and Balloon-Expandable Valves After Valve-in-Valve Transcatheter Aortic Valve Replacement in Patients With Small Surgical Prostheses
Authors: Aashish Gupta, Marloe Prince, Tamunoinemi Bob-Manuel, Mohammed Ahmed, James Jenkins, Tyrone Collins, Stephen Ramee, Jose Tafur Soto
Journal: Journal of the American College of Cardiology (2019)
High-fat, low-carbohydrate diet was associated with unfavourable impact on colonic luminal microenvironment
Authors: Yi Wan, Duo Li
Journal: Gut (2019)

We thank Ardalan et al for their interest and comments1 on our 6-month randomised controlled feeding trial, in which we have investigated the effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors.2 They indicated that the differences in microbial structure, faecal short-chain fatty acids concentrations and protein fermentation observed in our trial could be explained by the change in carbohydrates, especially the non-digestible carbohydrates like resistant starch (RS) and fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs), in company with the change in dietary fat due to the isocaloric design.

Our trial was designed based on the notion that the prevalence of obesity and type 2 diabetes had increased dramatically in parallel with a transition from the traditional low-fat, high-carbohydrates diet to a diet relatively …
TCT-254 Impact of the Aortic Annulus Maximal Diameter on Oversizing the Self-Expandable Valve (Medtronic) and on the Reduction of Post-Transcatheter Aortic Valve Implantation Paravalvular Leak
Authors: Sahbi Fradi, Bechara El Jourdi, Said Ghostine
Journal: Journal of the American College of Cardiology (2019)
Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia
Authors: Katherine Tarlock, Yuting He, James Sun, Rhonda E. Ries, Eric A Severson, Mark Bailey, Samantha Morley, Sohail Balasubramanian, Rachel Erlich, Doron Lipson, Geoff Otto, Jo-Anne Vergillo, Jeffrey S Ross, Tariq Mughal, Phil Stephens, Vincent Miller, Soheil Meshinchi, Jie He
Journal: Blood (2017)
Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
Authors: Xi Chen, Xiaohui Pan, Wenxin Zhang, Hongjie Guo, Shuyuan Cheng, Qiaojun He, Bo Yang, Ling Ding
Journal: Acta Pharmaceutica Sinica B (2019)

Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved remarkable success in treating multiple types of cancer. However, owing to the heterogeneity of tumors and individual immune systems, PD-L1/PD-1 blockade still shows slow response rates in controlling malignancies in many patients. Accumulating evidence has shown that an effective response to anti-PD-L1/anti-PD-1 therapy requires establishing an integrated immune cycle. Damage in any step of the immune cycle is one of the most important causes of immunotherapy failure. Impairments in the immune cycle can be restored by epigenetic modification, including reprogramming the environment of tumor-associated immunity, eliciting an immune response by increasing the presentation of tumor antigens, and by regulating T cell trafficking and reactivation. Thus, a rational combination of PD-L1/PD-1 blockade and epigenetic agents may offer great potential to retrain the immune system and to improve clinical outcomes of checkpoint blockade therapy.
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Authors: Sarah Waliany, Kristin L. Sainani, Lesley S. Park, Chiyuan Amy Zhang, Sandy Srinivas, Ronald M. Witteles
Journal: JACC CardioOncology (2019)

This study quantified the change in blood pressure (BP) during antivascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, compared BPs between TKIs, and analyzed change in BP during antihypertensive therapy.TKIs targeting VEGF are associated with hypertension. The absolute change in BP during anti-VEGF TKI treatment is not well characterized outside clinical trials.A retrospective single-center study included patients with metastatic renal cell carcinoma who received anti-VEGF TKIs between 2007 and 2018. Mixed models analyzed 3,088 BPs measured at oncology clinics.In 228 patients (baseline systolic blood pressure [SBP] 130.2 ± 16.3 mm Hg, diastolic blood pressure [DBP] 76.8 ± 9.3 mm Hg), anti-VEGF TKIs were associated with mean increases in SBP of 8.5 mm Hg (p < 0.0001) and DBP of 6.7 mm Hg (p <0.0001). Of the anti-VEGF TKIs evaluated, axitinib was associated with the greatest BP increase, with an increase in SBP of 12.6 mm Hg (p < 0.0001) and in DBP of 10.3 mm Hg (p < 0.0001) relative to baseline. In pairwise comparisons between agents, axitinib was associated with greater SBPs than cabozantinib by 8.4 mm Hg (p = 0.004) and pazopanib by 5.1 mm Hg (p = 0.01). Subsequent anti-VEGF TKI courses were associated with small increases in DBP, but not SBP, relative to the first course. During anti-VEGF TKI therapy, calcium-channel blockers and potassium-sparing diuretic agents were associated with the largest BP reductions, with decreases in SBP of 5.6 mm Hg (p < 0.0001) and 9.9 mm Hg (p = 0.007), respectively.Anti-VEGF TKIs are associated with increased BP; greatest increases are observed with axitinib. Calcium-channel blockers and potassium-sparing diuretic agents were associated with the largest reductions in BP.
US researchers and reviewers face increased scrutiny over foreign links
Authors: Owen Dyer
Journal: BMJ (2019)

The US National Institutes of Health (NIH) is not doing enough to identify potential conflicts of interest that could see research knowledge transferred abroad, says a series of three reports by the inspector general of the Department of Health and Human Services.123

The warning comes as the inspector general’s office is investigating about 250 mostly Chinese or Chinese-American academics suspected of sharing confidential research information with colleagues in their home country and, in some cases, of running “shadow labs” in China to mirror ongoing US research.

The US government is particularly concerned about China’s Thousand Talents programme, which China’s government describes as an effort to repatriate Chinese expertise from abroad but which Trump administration officials see as …
10 years of health-care reform in China: progress and gaps in Universal Health Coverage
Authors: Winnie Yip, Hongqiao Fu, Angela T Chen, Tiemin Zhai, Weiyan Jian, Roman Xu, Jay Pan, Min Hu, Zhongliang Zhou, Qiulin Chen, Wenhui Mao, Qiang Sun, Wen Chen
Journal: The Lancet (2019)
“When the Fall Is All There Is…”: Refocusing on the Critical (Unique?) Characteristic of “Dying” in Physician Aid-in-Dying
Authors: Virginia L. Bartlett, Stuart G. Finder
Journal: The American Journal of Bioethics (2019)

Geoffrey: My! You chivalric fool! As if the way one fell down mattered.Richard the Lionhearted: When the fall is all there is, it matters.(Goldman 1966)We are deeply appreciative of Kious and Batti...
A Dominant Negative SHP-2 Which Abrogates PD-1 Signalling Pathways and Restores Function of Cytotoxic CAR T Cells
Authors: Vania Baldan, Priyanka Ghongane, Evangelia Kokalaki, Wen Chean Lim, Shimobi Onuoha, Shaun Paul Cordoba, Simon Thomas, Martin Pule
Journal: Blood (2017)
Cognitive and brain structural changes in long-term oligodendroglial tumor survivors
Authors: Nuria Cayuela, Esteban Jaramillo-Jiménez, Estela Càmara, Carles Majós, Noemi Vidal, Anna Lucas, Miguel Gil-Gil, Francesc Graus, Jordi Bruna, Marta Simó
Journal: Neuro-Oncology (2019)

We identify cognitive impairment and MRI structural brain changes in long-term oligodendroglial tumor survivors treated with radiation therapy (RT) alone (21%) or with chemotherapy (CT) (79%).Oligodendroglial tumor patients (based on the World Health Organization [WHO] 2007 classification) who completed RT ± CT at least 2 years before the study initiation, were classified into 3 groups according to the time treatment was completed: Group 1 = 2-5 years (n = 22), Group 2 = 6-10 years (n = 13), and Group 3 >10 years (n = 13). All patients had a cross-sectional neuropsychological evaluation (n = 48) and a longitudinal volumetric analysis (gray matter [GM; n = 34]) between postsurgical and last follow-up MRI. White matter (WM) changes on MRI were assessed using a qualitative scale.There were no differences regarding tumor or treatment-related characteristics between groups. Six of 22 patients (27.3%) in Group 1; 5/13 (38.5%) in Group 2; and 9/13 (69.2%) in Group 3 had cognitive impairment that was considered severe in 3/22 patients (13.6%) in Group 1; 4/13 (30.8%) in Group 2; and 6/13 (46.2%) in Group 3. Patients in Groups 2 and 3 showed significant GM atrophy and more leukoencephalopathy than Group 1. Cognitive deficits were associated with brain atrophy and WM changes.Long-term oligodendroglial tumor survivors who underwent standard RT ± CT treatment, mainly >5 years of its completion, present cognitive impairment, especially on memory and executive functions, associated with late GM and WM damage, thus highlighting the need of developing future strategies in patients with oligodendroglial tumor and long expected survival.
CBT Curbs Internet and Gaming Addiction
Authors: Anita Slomski
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-826 Gender Disparities in Survival Outcomes in Acute Myocardial Infarction Complicated by Cardiogenic Shock Treated With Advanced Mechanical Circulatory Support
Authors: Michael Sobieraj, Anmol Singh, Tasveer Khawaja, Andrew Scatola, Jessica Gjonaj, Perwaiz Meraj
Journal: Journal of the American College of Cardiology (2019)
TCT-255 Impact of the Aortic Annulus Maximal Diameter on Oversizing the Self-Expandable Valve (Medtronic) and on the Reduction of Post-Transcatheter Aortic Valve Implantation Paravalvular Leak
Authors: Bechara El Jourdi, Sahbi Fradi, Said Ghostine
Journal: Journal of the American College of Cardiology (2019)
Neutrophils Deficient in Innate Suppressor IRAK-M Enhances Anti-tumor Immune Responses
Authors: Yao Zhang, Na Diao, Christina K. Lee, Hong Wei Chu, Lan Bai, Liwu Li
Journal: Molecular Therapy (2019)

Tumor-associated immune-suppressive neutrophils are prevalent in various cancers, including colorectal cancer. However, mechanisms of immune-suppressive neutrophils are not well understood. We report that a key innate suppressor, IRAK-M (interleukin-1 receptor-associated kinase M), is critically involved in the establishment of immune-suppressive neutrophils. In contrast to the wild-type (WT) neutrophils exhibiting immune-suppressive signatures of CD11bhighPD-L1highCD80low, IRAK-M-deficient neutrophils are rewired with reduced levels of inhibitory molecules PD-L1 and CD11b, as well as enhanced expression of stimulatory molecules CD80 and CD40. The reprogramming of IRAK-M-deficient neutrophils is mediated by reduced activation of STAT1/3 and enhanced activation of STAT5. As a consequence, IRAK-M-deficient neutrophils demonstrate enhanced capability to promote, instead of suppress, the proliferation and activation of effector T cells both in vitro and in vivo. Functionally, we observed that the transfusion of IRAK-M−/− neutrophils can potently render an enhanced anti-tumor immune response in the murine inflammation-induced colorectal cancer model. Collectively, our study defines IRAK-M as an innate suppressor for neutrophil function and reveals IRAK-M as a promising target for rewiring neutrophils in anti-cancer immunotherapy. Tumor-associated immune-suppressive neutrophils are prevalent in various cancers, including colorectal cancer. However, mechanisms of immune-suppressive neutrophils are not well understood. We report that a key innate suppressor, IRAK-M (interleukin-1 receptor-associated kinase M), is critically involved in the establishment of immune-suppressive neutrophils. In contrast to the wild-type (WT) neutrophils exhibiting immune-suppressive signatures of CD11bhighPD-L1highCD80low, IRAK-M-deficient neutrophils are rewired with reduced levels of inhibitory molecules PD-L1 and CD11b, as well as enhanced expression of stimulatory molecules CD80 and CD40. The reprogramming of IRAK-M-deficient neutrophils is mediated by reduced activation of STAT1/3 and enhanced activation of STAT5. As a consequence, IRAK-M-deficient neutrophils demonstrate enhanced capability to promote, instead of suppress, the proliferation and activation of effector T cells both in vitro and in vivo. Functionally, we observed that the transfusion of IRAK-M−/− neutrophils can potently render an enhanced anti-tumor immune response in the murine inflammation-induced colorectal cancer model. Collectively, our study defines IRAK-M as an innate suppressor for neutrophil function and reveals IRAK-M as a promising target for rewiring neutrophils in anti-cancer immunotherapy.
TCT-358 Clinical Impact of Intravascular Ultrasound Guidance in Stenting for Angiographically Moderate-to-Severe Calcified Coronary Lesion
Authors: Hanbit Park, Ju Hyeon Kim, Junho Hyun, Yeongjin Jeong, Yujin Yang, KyungJin Choe, Junghoon Lee, Tae oh Kim, Sangwoo Park, Sang-Cheol Cho, Euihong Ko, Do-Yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
Ignoring Data Delays Our Reaction to Emerging Public Health Tragedies Like <i>13 Reasons Why</i>—Reply
Authors: Thomas Niederkrotenthaler, Mark Sinyor, Benedikt Till
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
Authors: Yanhong Deng, Pan Chi, Ping Lan, Lei Wang, Weiqing Chen, Long Cui, Daoda Chen, Jie Cao, Hongbo Wei, Xiang Peng, Zonghai Huang, Guanfu Cai, Ren Zhao, Zhongcheng Huang, Lin Xu, Hongfeng Zhou, Yisheng Wei, Hao Zhang, Jian Zheng, Yan Huang, Zhiyang Zhou, Yue Cai, Liang Kang, Meijin Huang, Xiaojian Wu, Junsheng Peng, Donglin Ren, Jianping Wang
Journal: Journal of Clinical Oncology (2019)

PURPOSE In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results. METHODS Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m 2 , fluorouracil 400 mg/m 2 , and fluorouracil 2.4 g/m 2 over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m 2 on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS). RESULTS In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% ( P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% ( P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% ( P = .971 by log-rank test), respectively. CONCLUSION mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens.
Cardiovascular Toxicities Associated With Ibrutinib
Authors: Joe-Elie Salem, Ali Manouchehri, Marie Bretagne, Bénédicte Lebrun-Vignes, John D. Groarke, Douglas B. Johnson, Tao Yang, Nishitha M. Reddy, Christian Funck-Brentano, Jennifer R. Brown, Dan M. Roden, Javid J. Moslehi
Journal: Journal of the American College of Cardiology (2019)
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
Authors: E.J. Small, F. Saad, S. Chowdhury, S. Oudard, B.A. Hadaschik, J.N. Graff, D. Olmos, P.N. Mainwaring, J.Y. Lee, H. Uemura, P. De Porre, A.A. Smith, K. Zhang, A. Lopez-Gitlitz, M.R. Smith
Journal: Annals of Oncology (2019)

In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS) and time to symptomatic progression in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Overall survival (OS) results at the first interim analysis (IA1) were immature, with 104 of 427 (24%) events required for planned final OS analysis. Here, we report the results of a second pre-specified interim analysis (IA2).